{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T13:22:15Z","timestamp":1774099335061,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020647","name":"Diabetes Australia Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","award":["102539"],"award-info":[{"award-number":["102539"]}],"id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000971","name":"Diabetes Australia","doi-asserted-by":"publisher","award":["Y19G-BBER"],"award-info":[{"award-number":["Y19G-BBER"]}],"id":[{"id":"10.13039\/501100000971","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.hlc.2024.11.021","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T21:09:31Z","timestamp":1736975371000},"page":"118-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adeno-Associated Viruses as Gene Delivery Tools for Diabetic Heart Disease and Failure: Key Considerations for Clinicians and Preclinical Researchers"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4844-6437","authenticated-orcid":false,"given":"Kate L.","family":"Weeks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4534-0549","authenticated-orcid":false,"given":"Bianca C.","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2024.11.021_bib1","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2024.11.021_bib2","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and Heart Failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2024.11.021_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2024.11.021_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","article-title":"Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways","volume":"142","author":"Huynh","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.hlc.2024.11.021_bib5","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.hlc.2024.11.021_bib6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.hlc.2024.11.021_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12933-021-01245-2","article-title":"MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics","volume":"20","author":"Jakubik","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.hlc.2024.11.021_bib8","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.3390\/cells11193117","article-title":"In\u00a0vivo inhibition of miR-34a modestly limits cardiac enlargement and fibrosis in a mouse model with established type 1 diabetes-induced cardiomyopathy, but does not improve diastolic function","volume":"11","author":"Bernardo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.hlc.2024.11.021_bib9","doi-asserted-by":"crossref","first-page":"C482","DOI":"10.1152\/ajpcell.00446.2021","article-title":"Manipulation of the miR-378a\/mt-ATP6 regulatory axis rescues ATP synthase in the diabetic heart and offers a novel role for lncRNA Kcnq1ot1","volume":"322","author":"Durr","year":"2022","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.hlc.2024.11.021_bib10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.omtn.2022.07.007","article-title":"Therapeutic knockdown of miR-320 improves deteriorated cardiac function in a pre-clinical model of non-ischemic diabetic heart disease","volume":"29","author":"Ghosh","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.hlc.2024.11.021_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00109-023-02397-2","article-title":"A\u00a0gene therapy targeting medium-chain acyl-CoA dehydrogenase (MCAD) did not protect against diabetes-induced cardiac pathology","volume":"102","author":"Weeks","year":"2024","journal-title":"J\u00a0Mol Med (Berl)"},{"key":"10.1016\/j.hlc.2024.11.021_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.166713","article-title":"Cardiac gene therapy treats diabetic cardiomyopathy and lowers blood glucose","volume":"8","author":"Li","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.hlc.2024.11.021_bib13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1042\/CS20170063","article-title":"Phosphoinositide 3-kinase (p110\u03b1) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction","volume":"131","author":"Prakoso","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.hlc.2024.11.021_bib14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/cvr\/cvab043","article-title":"Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart","volume":"118","author":"Prakoso","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hlc.2024.11.021_bib15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cardfail.2009.01.013","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1\/2 clinical trial","volume":"15","author":"Jaski","year":"2009","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.hlc.2024.11.021_bib16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/gt.2015.109","article-title":"Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure","volume":"23","author":"Greenberg","year":"2016","journal-title":"Gene Ther"},{"key":"10.1016\/j.hlc.2024.11.021_bib17","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41569-019-0220-3","article-title":"G\u00a0protein-coupled receptor kinases as therapeutic targets in the heart","volume":"16","author":"Pfleger","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.hlc.2024.11.021_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/HCO.0000000000000386","article-title":"Cardiac gene therapy with adeno-associated virus-based vectors","volume":"32","author":"Chamberlain","year":"2017","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.hlc.2024.11.021_bib19","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.hlc.2018.03.005","article-title":"Adeno-associated virus gene therapy: translational progress and future prospects in the treatment of heart failure","volume":"27","author":"Bass-Stringer","year":"2018","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.hlc.2024.11.021_bib20","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.hlc.2024.11.021_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13395-024-00341-7","article-title":"Comparative in\u00a0vivo characterization of newly discovered myotropic adeno-associated vectors","volume":"14","author":"Ji","year":"2024","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.hlc.2024.11.021_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/gt.2010.105","article-title":"Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution","volume":"18","author":"Prasad","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.hlc.2024.11.021_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/cvr\/cvu174","article-title":"Rapid and highly efficient inducible cardiac gene knockout in adult mice using AAV-mediated expression of Cre recombinase","volume":"104","author":"Werfel","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hlc.2024.11.021_bib24","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1089\/hum.2017.188","article-title":"A\u00a0calsequestrin cis-regulatory motif coupled to a cardiac troponin T promoter improves cardiac adeno-associated virus Serotype 9 transduction specificity","volume":"29","author":"Chamberlain","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.hlc.2024.11.021_bib25","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1161\/CIRCULATIONAHA.123.065438","article-title":"MicroRNA-122-Mediated liver Detargeting enhances the tissue specificity of cardiac genome editing","volume":"149","author":"Yang","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2024.11.021_bib26","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41434-021-00243-z","article-title":"Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions","volume":"28","author":"Riyad","year":"2021","journal-title":"Gene Ther"},{"key":"10.1016\/j.hlc.2024.11.021_bib27","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: an integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.hlc.2024.11.021_bib28","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jacbts.2022.04.002","article-title":"Cardiac transduction in mini-pigs after low-dose retrograde coronary sinus infusion of AAV9-BAG3: a pilot study","volume":"7","author":"Myers","year":"2022","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.hlc.2024.11.021_bib29","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/eurheartj\/ehr447","article-title":"AAV6.\u03b2ARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model","volume":"34","author":"Raake","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2024.11.021_bib30","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/gt.2008.120","article-title":"Recirculating cardiac delivery of AAV2\/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals","volume":"15","author":"Byrne","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.hlc.2024.11.021_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/CIRCRESAHA.113.302421","article-title":"Long-term effects of AAV1\/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality","volume":"114","author":"Zsebo","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.hlc.2024.11.021_bib32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1752-8062.2010.00190.x","article-title":"Comparative cardiac gene delivery of adeno-associated virus serotypes 1\u20139 reveals that AAV6 mediates the most efficient transduction in mouse heart","volume":"3","author":"Zincarelli","year":"2010","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.hlc.2024.11.021_bib33","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV Serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.hlc.2024.11.021_bib34","first-page":"1901","article-title":"Coronary microvascular dysfunction in diabetes mellitus","volume":"45","author":"Kibel","year":"2017","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.hlc.2024.11.021_bib35","doi-asserted-by":"crossref","first-page":"H840","DOI":"10.1152\/ajpheart.00632.2019","article-title":"Gene therapy targeting cardiac phosphoinositide 3-kinase (p110\u03b1) attenuates cardiac remodeling in type 2 diabetes","volume":"318","author":"Prakoso","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"10.1016\/j.hlc.2024.11.021_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1459","article-title":"Emerging roles of RNA-binding proteins in diabetes and their therapeutic potential in diabetic complications","volume":"9","author":"Nutter","year":"2018","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"10.1016\/j.hlc.2024.11.021_bib37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2337\/db11-0763","article-title":"Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in Type 1 diabetic mice","volume":"61","author":"Meloni","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.hlc.2024.11.021_bib38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12012-021-09706-6","article-title":"AAV9-mediated cardiac CNTF overexpression exacerbated adverse cardiac remodeling in streptozotocin-induced type 1 diabetic models","volume":"22","author":"Zhong","year":"2022","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.hlc.2024.11.021_bib39","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/CIRCRESAHA.110.239111","article-title":"Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling","volume":"108","author":"Katare","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.hlc.2024.11.021_bib40","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3389\/fphar.2018.01090","article-title":"Generation of MicroRNA-34 sponges and tough decoys for the heart: developments and challenges","volume":"9","author":"Bernardo","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.hlc.2024.11.021_bib41","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1042\/CS20171269","article-title":"Gene delivery of medium chain acyl-coenzyme A dehydrogenase induces physiological cardiac hypertrophy and protects against pathological remodelling","volume":"132","author":"Bernardo","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.hlc.2024.11.021_bib42","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/CIRCHEARTFAILURE.112.966622","article-title":"Phosphoinositide 3-kinase p110alpha is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction","volume":"5","author":"Weeks","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hlc.2024.11.021_bib43","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1089\/hgtb.2012.105","article-title":"Comparison of adeno-associated virus serotypes and delivery methods\u00a0for cardiac gene transfer","volume":"23","author":"Fang","year":"2012","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.hlc.2024.11.021_bib44","article-title":"Gene therapy advances: a meta-analysis of AAV usage in clinical settings","volume":"8","author":"Au","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.hlc.2024.11.021_bib45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5694\/mja2.51629","article-title":"Clinical gene technology in Australia: building on solid foundations","volume":"217","author":"O\u2019Sullivan","year":"2022","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2024.11.021_bib46","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41587-022-01346-7","article-title":"Gene therapy at the crossroads","volume":"40","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.hlc.2024.11.021_bib47","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14712598.2022.2060737","article-title":"Addressing high dose AAV toxicity\u2014\u2018one\u00a0and done\u2019 or \u2018slower and lower\u2019?","volume":"22","author":"Kishimoto","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.hlc.2024.11.021_bib48","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1089\/hum.2021.129","article-title":"Repeated systemic dosing of adeno-associated virus vectors in immunocompetent mice after blockade of T cell costimulatory pathways","volume":"33","author":"Zhong","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.hlc.2024.11.021_bib49","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1161\/CIRCRESAHA.120.315855","article-title":"Gene therapy for the heart lessons learned and future perspectives","volume":"126","author":"Cannat\u00e0","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.hlc.2024.11.021_bib50","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.recesp.2023.06.016","article-title":"Gene therapy for heart failure and cardiomyopathies","volume":"76","author":"Argir\u00f2","year":"2023","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.hlc.2024.11.021_bib51","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis","year":"2013","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.hlc.2024.11.021_bib52","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Costa Verdera","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.hlc.2024.11.021_bib53","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.122.063759","article-title":"Extracellular vesicle-encapsulated adeno-associated viruses for therapeutic gene delivery to the heart","volume":"148","author":"Li","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2024.11.021_bib54","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.hlc.2018.08.014","article-title":"Directed evolution of adeno-associated virus vectors in human cardiomyocytes for cardiac gene therapy","volume":"27","author":"Kok","year":"2018","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.hlc.2024.11.021_bib55","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.omtm.2023.08.010","article-title":"Development of new adeno-associated virus capsid variants for targeted gene delivery to human cardiomyocytes","volume":"30","author":"Kok","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.hlc.2024.11.021_bib56","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/biosci\/biv084","article-title":"Extracellular vesicles: composition, biological relevance, and methods of study","volume":"65","author":"Zaborowski","year":"2015","journal-title":"Bioscience"},{"key":"10.1016\/j.hlc.2024.11.021_bib57","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1039\/D2CB00231K","article-title":"A\u00a0primer to directed evolution: current methodologies and future directions","volume":"4","author":"Sell\u00e9s Vidal","year":"2023","journal-title":"RSC Chem Biol"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950624019231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950624019231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T22:07:24Z","timestamp":1740607644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950624019231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1443950624019231"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2024.11.021","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adeno-Associated Viruses as Gene Delivery Tools for Diabetic Heart Disease and Failure: Key Considerations for Clinicians and Preclinical Researchers","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2024.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).","name":"copyright","label":"Copyright"}]}}